Navigation Links
Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
Date:3/4/2013

LA JOLLA, Calif., March 4, 2013Sanford-Burnham Medical Research Institute (Sanford-Burnham) and 60 Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics. 60 Pharmaceuticals, a philanthropic-for-profit company focused on neglected and rare diseases, agreed to provide funding to Sanford-Burnham for the first phase of research to explore inhibitors of furin.

Since viral genomes are too small to encode every protein needed for their survival, they take advantage of proteins in their human hosts. For the dengue virus and numerous other virusessuch as West Nile, Ebola, or yellow feverfurin is a vital host protein. For this reason, these viruses can only attack human cells that produce furin. Scientists at Sanford-Burnham are now trying to find a way to inhibit furin, making it impossible for the dengue virus to exploit and "hijack" a host cell.

"We're working on a new small-molecule furin inhibitor. It's a challenge to design, but could solve the toxicity problem that plagues existing viral inhibitors," explains Alex Strongin, Ph.D., professor in Sanford-Burnham's Infectious and Inflammatory Disease Center.

During the first phase of the research partnership, Drs. Alex Strongin and Maurizio Pellecchia and their laboratories at Sanford-Burnham will identify the most promising lead candidate from multiple small-molecule compounds they have already synthesized and tested in cell-based tests. They will evaluate each compound's absorption and distribution in the body (pharmacokinetics), as well as toxicity and efficacy in animal models. These data will inform potential second-phase research, which will focus on further developing the lead compound for oral application.

"The partnership with Sanford-Burnham exemplifies our commitment to developing treatments for the world's most
'/>"/>

Contact: Deborah Robison
drobison@sanfordburnham.org
407-745-2073
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Californias stem cell agency boosts heart disease research at Sanford-Burnham
2. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
3. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
6. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
9. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
10. Researchers pursue red flag for schizophrenia relapse
11. University of Arizona Engineering College pursues water technology innovation cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... red wormlike insects that nibble on the plant's leaves ... larvae that survive eventually evolve methods to overcome plant ... trying to thwart the insect have identified Hessian fly ... itself from the munching larvae. The researchers report their ...
... target organs or cell types, you need a good ... the target in question could do the trick. , ... tiny capsules require preorganized structures or "molds" to shape ... synthetic or purification procedure. Korean researchers led by Kimoon ...
... have discovered how cells fine-tune their oxygen use to make ... Too little oxygen threatens life by compromising mitochondria that power ... by replacing one protein with an energy-efficient substitute that "is ... begins to run out of gas," says Gregg Semenza, M.D., ...
Cached Biology News:Scientists find genes involved in the battle between Hessian flies and wheat 2Scientists find genes involved in the battle between Hessian flies and wheat 3Navigable nanotransport 2Need oxygen? Cells know how to spend and save 2
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... GMO corn cases filed across the United States, ... of being consolidated in a Kansas federal court for pretrial ... 162 Corn Litigation, MDL No. 2591 in the U.S. District ... Syngenta GMO corn multidistrict litigation (MDL) has been handed over ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Nventa Biopharmaceuticals,Corporation (TSX: NVN) today announced financial results for ... and highlighted several,recent product developments and corporate milestones., ... Recent product and corporate highlights:, o ... it will initiate a ...
... Risks of Progression of,Vertebral Fracture in US-Caucasian Women, ... (Amex: ILI ), announced today that Nazneen ... Development, will present new research,findings on the genetics ... the,American Society of Human Genetics, which takes place ...
... LLC, a privately-held,biopharmaceutical company focused on developing novel ... Sindbis viral vector, announced today,that it has appointed ... immediately, to lead the company,s next phase of ... Stonebanks will serve on Cynvec,s Board,of Directors., ...
Cached Biology Technology:Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 2Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 3Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 4Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 5Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 6Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 7Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 2Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 3Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 2Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 3
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: